Krystal Biotech (NASDAQ:KRYS) PT Raised to $220.00 at Stifel Nicolaus

Krystal Biotech (NASDAQ:KRYS) had its target price upped by Stifel Nicolaus from $204.00 to $220.00 in a report published on Wednesday, Benzinga reports. They currently have a buy rating on the stock.

A number of other analysts have also recently weighed in on the stock. Cantor Fitzgerald reissued an overweight rating on shares of Krystal Biotech in a report on Thursday, August 29th. William Blair upgraded Krystal Biotech to a strong-buy rating in a research note on Friday, August 30th. Evercore ISI raised their target price on Krystal Biotech from $201.00 to $206.00 and gave the company an outperform rating in a research note on Monday, August 12th. Citigroup reissued a neutral rating and set a $204.00 target price (up from $195.00) on shares of Krystal Biotech in a research note on Tuesday, August 6th. Finally, Chardan Capital raised their price target on shares of Krystal Biotech from $153.00 to $208.00 and gave the company a buy rating in a research note on Monday, August 5th. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of Buy and a consensus target price of $196.75.

Krystal Biotech Stock Performance

Shares of NASDAQ KRYS opened at $201.58 on Wednesday. The stock’s 50-day simple moving average is $196.03 and its 200-day simple moving average is $178.64. Krystal Biotech has a 1 year low of $93.95 and a 1 year high of $219.34. The firm has a market cap of $5.79 billion, a price-to-earnings ratio of 107.80 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, August 5th. The company reported $0.53 EPS for the quarter, topping analysts’ consensus estimates of $0.50 by $0.03. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The business had revenue of $70.28 million during the quarter, compared to the consensus estimate of $65.27 million. During the same period last year, the firm earned ($1.25) earnings per share. The company’s revenue for the quarter was up 70283900.0% compared to the same quarter last year. As a group, research analysts predict that Krystal Biotech will post 3.13 EPS for the current year.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the sale, the insider now owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 14.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

Institutional investors have recently modified their holdings of the company. EFG Asset Management North America Corp. grew its position in shares of Krystal Biotech by 0.5% in the second quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company’s stock valued at $2,308,000 after purchasing an additional 60 shares during the last quarter. GAMMA Investing LLC increased its position in Krystal Biotech by 160.3% during the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after acquiring an additional 93 shares during the period. Nisa Investment Advisors LLC boosted its holdings in Krystal Biotech by 11.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock valued at $173,000 after purchasing an additional 94 shares during the period. Arizona State Retirement System grew its position in Krystal Biotech by 2.1% in the 2nd quarter. Arizona State Retirement System now owns 5,147 shares of the company’s stock worth $945,000 after purchasing an additional 108 shares during the last quarter. Finally, Fiera Capital Corp increased its stake in Krystal Biotech by 0.8% during the second quarter. Fiera Capital Corp now owns 16,208 shares of the company’s stock valued at $2,976,000 after acquiring an additional 130 shares during the period. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).